Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis
- 1 September 2016
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 68 (3) , 392-401
Abstract
No abstract availableKeywords
Funding Information
- Pharmalink AB
- REDINREN (RD012/0021)
- Instituto de Salud Carlos III (10/02668, 13/02502, ICI 14/00350)
This publication has 50 references indexed in Scilit:
- The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathyClinical and Experimental Nephrology, 2012
- Corticosteroid Therapy in IgA NephropathyJournal of the American Society of Nephrology, 2012
- IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprineJournal Of Nephrology, 2012
- Proteinuria as a surrogate end point—more data are neededNature Reviews Nephrology, 2012
- Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult populationNephrology Dialysis Transplantation, 2011
- Addition of Azathioprine to Corticosteroids Does Not Benefit Patients with IgA NephropathyJournal of the American Society of Nephrology, 2010
- Blood pressure as an example of a biomarker that functions as a surrogateThe AAPS Journal, 2006
- Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized studyKidney International, 2004
- On meta-analytic assessment of surrogate outcomesBiostatistics, 2000
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992